| Primary |
| Prostate Cancer Stage Iv |
18.3% |
| Prostate Cancer |
17.0% |
| Product Used For Unknown Indication |
12.7% |
| Prostate Cancer Stage Ii |
8.6% |
| Hypertension |
7.3% |
| Drug Use For Unknown Indication |
7.0% |
| Prostate Cancer Stage Iii |
5.5% |
| Benign Prostatic Hyperplasia |
4.4% |
| Breast Cancer |
2.5% |
| Constipation |
2.4% |
| Gastritis |
2.2% |
| Diabetes Mellitus |
2.1% |
| Angina Pectoris |
1.5% |
| Endometriosis |
1.5% |
| Prophylaxis |
1.3% |
| Gastric Ulcer |
1.3% |
| Cancer Pain |
1.3% |
| Cardiac Failure |
1.1% |
| Cerebral Infarction |
1.1% |
| Pain |
1.0% |
|
| Prostate Cancer |
18.3% |
| Death |
10.8% |
| Interstitial Lung Disease |
10.3% |
| Pneumonia |
9.0% |
| Prostate Cancer Stage Iv |
5.8% |
| Prostatic Specific Antigen Increased |
5.2% |
| Myocardial Infarction |
4.3% |
| Cardiac Failure |
3.9% |
| Lung Neoplasm Malignant |
3.6% |
| Pneumonia Aspiration |
3.3% |
| Cerebral Infarction |
3.0% |
| Gastric Cancer |
2.9% |
| Injection Site Induration |
2.9% |
| Pancreatic Carcinoma |
2.9% |
| Respiratory Failure |
2.9% |
| Hot Flush |
2.5% |
| Pyrexia |
2.5% |
| Pleural Effusion |
2.2% |
| Vomiting |
1.9% |
| Hepatic Function Abnormal |
1.8% |
|
| Secondary |
| Prostate Cancer |
18.1% |
| Prostate Cancer Stage Iv |
17.5% |
| Drug Use For Unknown Indication |
9.2% |
| Prostate Cancer Stage Ii |
8.6% |
| Product Used For Unknown Indication |
6.5% |
| Prostate Cancer Stage Iii |
5.6% |
| Hypertension |
5.5% |
| Benign Prostatic Hyperplasia |
3.8% |
| Gastritis |
3.5% |
| Cancer Pain |
2.9% |
| Diabetes Mellitus |
2.9% |
| Pain |
2.3% |
| Breast Cancer |
2.2% |
| Prophylaxis |
2.1% |
| Constipation |
1.9% |
| Prostate Cancer Metastatic |
1.7% |
| Antiandrogen Therapy |
1.5% |
| Neurogenic Bladder |
1.5% |
| In Vitro Fertilisation |
1.5% |
| Angina Pectoris |
1.3% |
|
| Prostate Cancer |
13.2% |
| Pneumonia |
8.6% |
| Injection Site Induration |
8.0% |
| Pneumonia Aspiration |
7.7% |
| Prostatic Specific Antigen Increased |
5.8% |
| Interstitial Lung Disease |
5.5% |
| Off Label Use |
5.5% |
| Cardiac Failure |
5.2% |
| Pulmonary Oedema |
5.2% |
| Respiratory Failure |
5.2% |
| Pain In Extremity |
3.4% |
| Gastric Cancer |
3.1% |
| Injection Site Pain |
3.1% |
| Myocardial Infarction |
3.1% |
| Prostate Cancer Stage Iv |
3.1% |
| Subdural Haematoma |
3.1% |
| White Blood Cell Count Decreased |
3.1% |
| Cardiac Disorder |
2.8% |
| Epilepsy |
2.8% |
| Liver Disorder |
2.8% |
|
| Concomitant |
| Prostate Cancer |
22.7% |
| Prostate Cancer Metastatic |
13.8% |
| Product Used For Unknown Indication |
10.6% |
| Cancer Pain |
7.3% |
| Hypertension |
6.4% |
| Prophylaxis |
5.3% |
| General Physical Condition |
4.6% |
| Metastases To Bone |
4.2% |
| Hormone Therapy |
4.0% |
| Pain |
3.2% |
| Constipation |
3.0% |
| Breast Cancer |
2.9% |
| Drug Use For Unknown Indication |
2.0% |
| Nausea |
1.7% |
| Depression |
1.5% |
| Vitamin Supplementation |
1.5% |
| Abdominal Pain |
1.4% |
| Diabetes Mellitus |
1.4% |
| Anxiety |
1.3% |
| Gastrooesophageal Reflux Disease |
1.3% |
|
| Sepsis |
12.9% |
| Osteonecrosis Of Jaw |
8.8% |
| Dyspnoea |
6.9% |
| Interstitial Lung Disease |
6.9% |
| Urinary Retention |
6.9% |
| Vomiting |
5.5% |
| Anaemia |
4.6% |
| General Physical Health Deterioration |
4.1% |
| Rash |
4.1% |
| Rhabdomyolysis |
4.1% |
| Device Leakage |
3.7% |
| Haemoglobin Decreased |
3.7% |
| Osteonecrosis |
3.7% |
| Prostate Cancer |
3.7% |
| Pyrexia |
3.7% |
| Visual Acuity Reduced |
3.7% |
| Hepatic Failure |
3.2% |
| Pain |
3.2% |
| Pneumonia |
3.2% |
| Syncope |
3.2% |
|
| Interacting |
| Prostate Cancer |
33.3% |
| Product Used For Unknown Indication |
30.0% |
| Hormone Therapy |
23.3% |
| In Vitro Fertilisation |
13.3% |
|
| International Normalised Ratio Decreased |
36.4% |
| Drug Interaction |
18.2% |
| Neutropenia |
18.2% |
| Dehydration |
9.1% |
| Ovarian Hyperstimulation Syndrome |
9.1% |
| Renal Failure |
9.1% |
|
